Myo-inositol and D-chiro-inositol are involved in cellular signalling, including pathways the body uses to respond to insulin. That puts them upstream of a much wider conversation around glucose regulation, metabolic health, SHBG, androgen availability and reproductive function.

Let's put it simply: hormones get the attention. The signalling pathway comes first.

Start with insulin, not hormones

When you eat carbohydrates, blood glucose rises and the pancreas releases insulin. Most people know that part.

What gets missed is that making insulin is only half the job. Your cells also need to respond to the message.

Think of insulin binding to its receptor as the knock at the door. A chain of signals inside the cell then helps turn that knock into action, including moving glucose towards cells where it can be used or stored. Inositol-derived messengers are involved in parts of that signalling system.

That is why myo-inositol and D-chiro-inositol have been studied in glucose metabolism and insulin-resistant states, not just reproductive health.

A systematic review and meta-analysis of 20 randomised controlled trials found reductions in fasting glucose, fasting insulin and HOMA-IR across the included inositol studies. The important caveat is that the trials covered different populations and formulations, so this is a signal across the research rather than a promise of the same response in everyone.

Insulin must be heard, not just made

When tissues become less responsive to insulin, the body can compensate by producing more of it. For a while, that can keep glucose looking relatively normal.

So a normal glucose result does not always mean the metabolic picture is perfect. The body may simply be working harder to keep it there.

Lower insulin sensitivity -> greater insulin demand -> potentially higher circulating insulin.

And higher insulin does not stay in the blood-sugar lane. It overlaps with other endocrine pathways, which is where SHBG enters the conversation.

Where SHBG comes in

Sex Hormone-Binding Globulin, or SHBG, is made mainly by the liver. It binds sex hormones including testosterone and oestradiol.

That matters because total testosterone and available testosterone are not the same thing. If SHBG changes, the proportion of testosterone that is free or available can change with it.

Insulin-resistant and hyperinsulinaemic states are commonly associated with lower SHBG. So sometimes the better question is not just 'what is your testosterone?' but 'what does that testosterone look like in the context of SHBG and metabolic health?'

This is one reason inositol research reaches into androgen markers. Meta-analyses in PMOS/PCOS populations have reported changes in SHBG, total testosterone and free-androgen measures, although the size and consistency of the response vary by study and by metabolic phenotype.

Why PMOS gets most of the attention

PMOS, polyendocrine metabolic ovarian syndrome, formerly known as PCOS, is where inositol became a mainstream supplement conversation.

The link makes biological sense. Insulin resistance is common in PMOS, higher insulin can interact with ovarian androgen production, and metabolic health can influence SHBG. That creates a genuine bridge between insulin signalling and reproductive endocrinology.

But this is where supplement marketing can get ahead of the evidence.

The international evidence-based guideline says inositol can be considered according to individual preference, with potential improvement in some metabolic measures, but it also describes the clinical benefits as limited and says a specific type, dose or combination cannot currently be recommended because the quality of evidence is not strong enough.

The honest headline: there is enough research to make inositol interesting. There is not enough to pretend it is a universal fix for PMOS.

Myo-inositol and D-chiro-inositol are related, not identical

There are several forms of inositol, but myo-inositol (MI) and D-chiro-inositol (DCI) are the two that dominate the metabolic and reproductive research.

The body can convert myo-inositol into D-chiro-inositol, and the two forms are involved in overlapping but not identical signalling pathways. Research has explored both in insulin signalling, glucose metabolism and ovarian steroid signalling.

That is why you will see formulas using MI and DCI together rather than treating every form of inositol as interchangeable.

What about the 40:1 ratio?

If you have spent five minutes researching inositol, you have probably seen 40:1 presented as the ratio.

There is research behind it. A small, randomised trial comparing seven MI:DCI ratios in 56 people with PCOS reported the strongest results in the 40:1 group for ovulation and several hormonal and metabolic measures.

But 56 people split across seven groups is not enough to turn one ratio into a universal biological rule.

The current international guideline is much more cautious and says the evidence is not strong enough to recommend a specific form or combination for everyone. Dosage matters more at the current research level.

So the sensible position is straightforward: ratio matters enough to research, but the science is not finished.

This is not just a women's health ingredient

The other part of the conversation that gets missed is male reproductive health.

Sperm motility is energy intensive. Mitochondrial function matters, cellular signalling matters, and myo-inositol has been investigated in that context.

A 2024 systematic review and meta-analysis covering 16 studies reported improvements in total and progressive sperm motility with myo-inositol. It also reported a reduction in sperm DNA fragmentation, although that result varied substantially between studies.

That is promising. It is not the same as saying myo-inositol treats male infertility.

Better semen parameters are useful markers. Pregnancy and live birth are outcomes. They are not interchangeable.

Markers are not outcomes

This is the bit worth remembering across the whole inositol conversation.

A lower fasting insulin is not automatically fat loss. A change in SHBG is not automatically symptom resolution. Better sperm motility is not automatically a pregnancy. And a supplement that affects a useful biomarker is not automatically a treatment for the condition linked to it.

Good research is about being interested without overselling the result.

That is also why the current guideline remains cautious about inositol specifically as a fertility therapy in PMOS: evidence for ovulation, clinical pregnancy and live birth is still uncertain.

So what would you actually look at?

There is no single 'inositol blood test'. If you are taking it for a specific reason, the useful question is what pathway you are actually trying to influence.

• Glucose, HbA1c and, where appropriate, fasting insulin for metabolic context.

• SHBG and testosterone when androgen availability is part of the picture.

• Lipids and liver markers for the wider metabolic picture.

• Thyroid markers where symptoms or SHBG interpretation make them relevant.

• FSH, LH, oestradiol and progesterone where reproductive hormone assessment is appropriate.

• Semen analysis when male fertility is the actual concern.

Testing does not tell you that you 'need' inositol. What it can do is stop you guessing about the physiology you are trying to change.

The practical takeaways

• Inositol is more than a hormone supplement. Its biology starts with cellular signalling, including insulin-related pathways.

• Myo-inositol and D-chiro-inositol are related but not identical, which is why formulation matters.

• There is reasonable evidence for effects on some metabolic and biochemical markers, but responses are not uniform.

• PMOS is where most of the evidence sits, but current guidance is still cautious about making broad clinical or fertility claims.

• Myo-inositol also has emerging evidence in male reproductive health, particularly sperm motility.

• One ratio, one supplement or one biomarker never tells the whole story.

The bottom line

Inositol has been boxed into the 'female hormone supplement' category for too long.

The current evidence is more interesting than that. It sits across insulin signalling, glucose regulation, SHBG, androgen availability and reproductive physiology in both women and men.

That does not mean everyone needs it, and it does not mean every promising biomarker result translates into a clinical outcome.

It means there is a real pathway worth understanding, and a good reason to care about the context behind the supplement, rather than just the label on the front.

Myo & D-Chiro Inositol combines both forms in a single formula. If any of the situations above apply to you, speak to a suitably qualified healthcare professional first.

Medical disclaimer: This article is for general information and is not medical advice. Food supplements should not be used as a substitute for a varied, balanced diet and a healthy lifestyle. If you are pregnant, trying to conceive, managing a health condition or taking medication, speak to a suitably qualified healthcare professional before starting a new supplement.

References

1. Bevilacqua A, Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism. International Journal of Endocrinology. 2018;2018:1968450. PMID 30595691. DOI 10.1155/2018/1968450.

2. Miñambres I, Cuixart G, Gonçalves A, Corcoy R. Effects of inositol on glucose homeostasis: systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition. 2019;38(3):1146-1152. PMID 29980312. DOI 10.1016/j.clnu.2018.06.957.

3. Paolacci S, et al. From Myo-inositol to D-chiro-inositol molecular pathways. European Review for Medical and Pharmacological Sciences. 2021;25(5):2390-2402. PMID 33755975. DOI 10.26355/eurrev_202103_25279.

4. Fitz V, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-1655. PMID 38163998. DOI 10.1210/clinem/dgad762.

5. International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (PMOS), updated nomenclature 2026. Monash University / International Guideline Network.

6. Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences. 2019;23(12):5512-5521. PMID 31298405. DOI 10.26355/eurrev_201906_18223.

7. Ghaemi M, et al. The effect of Myo-inositol on improving sperm quality and IVF outcomes: A systematic review and meta-analysis. Food Science & Nutrition. 2024;12(11):8515-8524. PMID 39619962. DOI 10.1002/fsn3.4427.

8. Tienforti D, et al. Metabolic Phenotype Predicts Biochemical Response to Inositol Supplementation in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Clinical Endocrinology. 2026. PMID 41947399.